Investment Rating - The report assigns an "Outperform" rating for the company [4] Core Insights - The company is a high-quality private coal enterprise transitioning from a single coal producer to a diversified coal producer, with a focus on expanding its product range and geographical reach [1][15] - The main coal mine, Dafenpu, has strong profitability and is a key driver of revenue and cash flow growth [1][32] - The company is expanding its coal business into coking coal with two new mines under construction, which are expected to enhance revenue [2][46] - The company is also diversifying into non-coal mining and other businesses, which are projected to contribute additional revenue streams [3][54] Summary by Sections Company Overview - The company is a private integrated coal enterprise listed in Hong Kong since March 2012, with a high concentration of ownership [1][15] - As of June 30, 2025, the controlling shareholder holds 62.96% of the shares, indicating a strong governance structure [1][15] Coal Business Expansion - The company is transitioning from a single coal type producer to a full-spectrum coal producer, with a projected revenue contribution of approximately 95% from coal business by 2024 [1][32] - Dafenpu coal mine has a production capacity of 6.5 million tons per year and is recognized for its high-quality, low-sulfur coal [1][32] - The company is developing two new coking coal mines, Yong'an and Wei Yi, with expected production capacities of 1.2 million tons and 0.9 million tons respectively [2][46] Financial Performance - The company has shown a steady improvement in financial health, with a significant reduction in debt-to-asset ratio from 68% in 2013 to 24% in 2021 [4][26] - The company has a consistent dividend policy, with a total dividend payout ratio of 56.6% in 2024 [4][26] - Revenue and net profit forecasts for 2025-2027 are projected at 13.1 billion, 17.0 billion, and 20.2 billion yuan respectively, with corresponding PE ratios of 10.6, 8.2, and 6.9 [4][8] Non-Coal Business Development - The company is diversifying into non-coal mining, with a significant project in Sierra Leone expected to generate additional revenue [3][56] - The company is also expanding into agriculture and real estate, with multiple projects underway that are anticipated to enhance overall revenue [59]

证券研究报告 | 2026年02月09日 中国东方教育（00667.HK） 优于大市 模式升级固本培元，职教龙头弄潮服务消费新风口 深耕职教近四十年，多品牌构筑技能培训版图。中国东方教育是国内领先的 职业技能教育集团，旗下布局新东方烹饪、新华电脑、万通汽修等知名品牌。 2019 年在港股上市。公司覆盖烹饪技术、西点西餐、信息及互联网技术、汽 车服务四大成熟专业，并积极布局美业、宠物、康养等新兴专业。 技能培训行业：职教万亿扩容，中职调整寻机。我国职业教育行业处于万亿 扩容黄金期，受政策持续加码与产业需求拉动双轮驱动，2025-2029 年预计 维持 17%复合增速，2029 年市场规模有望突破 2 万亿元。此前中职赛道经历 数年调整，2010-2024 年在高中招生占比从 51%下滑至 34%，但考虑中级技能 人才产业刚需、部分普高适配度较低学生回流，后续普高比有望寻找新平衡。 成熟专业：疫后盈利能力率先修复，收入后提速打开利润增长空间。2024 年以来公司积极调整，关停并转低效校区、推进五省职教产业园建设、升级 课程结构，带动 2025H1 公司经调净利率 19.0%/+5.0pct；预计伴随更多职教 园区 ...

Investment Rating - The report does not explicitly state the investment rating for Innovent Biologics Core Insights - Innovent Biologics has entered into its seventh global strategic collaboration with Eli Lilly, focusing on the development of innovative drugs in oncology and immunology, with a deal size that exceeds expectations [1][4] - Innovent will lead the R&D work from drug discovery to Proof of Concept (PoC) in China, while retaining all rights in Greater China, which signifies international recognition of its R&D capabilities [2][5] - The collaboration is expected to strengthen Innovent's financial position through an upfront payment of USD 350 million and potential milestone payments of up to approximately USD 8.5 billion [1][4][6] - The focus on oncology and immunology aligns with Innovent's existing core pipeline, enhancing its overall competitiveness [2][6] Summary by Sections Strategic Collaboration - Innovent and Eli Lilly's collaboration will leverage Innovent's mature antibody technology platform and efficient clinical capabilities, reducing overseas development risks while enhancing efficiency through Lilly's global network [2][5] - The collaboration allows Innovent to lead early-stage R&D and retain rights in Greater China, marking a significant step in the globalization of Chinese innovative biopharmaceutical companies [5][6] Financial Implications - The upfront and milestone payments from the collaboration will provide a financial safety net for Innovent, while sales royalties will enable long-term benefits from global market growth [6] - Management projects that Innovent will achieve revenue of CNY 20 billion by 2027, with five products expected to enter MRCT Phase III clinical stages by 2030 [8] Pipeline and Market Potential - Innovent's oncology pipeline is expected to maintain its core market position, with additional growth drivers from integrated pipelines such as Mazdutide, Tolecimab, and Tetumumab [8] - Three assets, including IBI363, IBI343, and IBI324, are set to advance to global multi-regional Phase III clinical stages, with a combined market potential estimated at USD 60 billion [8]

Investment Rating - The report gives a "Buy" rating for the company, marking its first coverage in the market [4][6]. Core Insights - The company is a leader in the African hygiene products industry, with a projected revenue of $450 million in 2024 and a three-year CAGR of 19%. Net profit is expected to reach $95 million, with a CAGR of 130% [1][4]. - The African hygiene products market is still in its early industrialization stage, presenting significant growth potential. The market for baby diapers, pull-ups, and sanitary pads is estimated to be $3.8 billion in 2024, with a projected growth rate of approximately 8% over the next five years [2][40]. - The company has established competitive barriers through a multi-brand strategy, a robust local supply chain, and a mature sales network, covering over 30 African countries and reaching more than 80% of the local population [3][62]. Summary by Sections Company Overview - The company, established in 2009, has become a leading brand in Africa's hygiene products sector, launching several brands including Softcare, Maya, Veesper, Cuettie, and Clincleer [1][16]. Market Potential - Africa's GDP is expected to grow at around 4%, with a high birth rate of approximately 4% and a low penetration rate of hygiene products (20% for diapers compared to 80% in developed markets) [2][40]. - The market for disposable hygiene products in Africa is projected to grow significantly, with the baby diaper market expected to reach $2.59 billion by 2024, growing at a CAGR of 6.2% [49]. Competitive Advantages - The company has a diverse brand portfolio that covers various market segments, with Softcare being the leading brand in terms of sales volume [3][62]. - The company has developed a comprehensive sales network and local manufacturing capabilities, with eight factories across Africa, making it the largest local manufacturer in the hygiene products sector [3][62]. Financial Analysis - The company’s revenue is projected to grow from $411 million in 2023 to $454 million in 2024, with a net profit increase from $64.68 million to $95.11 million during the same period [5][24]. - The expected earnings per share for 2024 is $0.19, with a price-to-earnings ratio of 2.39 [5][4]. Investment Forecast - Revenue projections for 2025-2027 are estimated at $529 million, $610 million, and $703 million respectively, with corresponding net profits of $115 million, $133 million, and $156 million [4][5].

Investment Rating - The report assigns an "Outperform" rating for the company [4] Core Insights - The company is a high-quality private coal enterprise transitioning from a single coal producer to a diversified coal producer, with a focus on expanding its product range and regional presence [1][15] - The main coal mine, Dafenpu, has strong profitability and is a key driver of revenue and cash flow growth [1][32] - The company is expanding its coal business into coking coal with two new mines under construction, which are expected to enhance revenue [2][46] - The company is also diversifying into non-coal mining, with a significant project in Sierra Leone expected to contribute additional revenue [3][54] - The company has a strong dividend policy, with increasing frequency and rates of dividends reflecting its solid financial performance [4][26] Summary by Sections Company Overview - The company is a private integrated coal enterprise listed in Hong Kong since March 2012, with a high concentration of ownership [1][15] - It operates several coal mines and is expanding into international markets, particularly in South Africa [15][52] Coal Business Expansion - The company is transitioning from a focus on thermal coal to a broader range of coal products, including coking coal, with new mines expected to start production in 2026 [2][46] - The Dafenpu mine has a production capacity of 6.5 million tons per year and is recognized for its high-quality coal [1][32] Financial Performance - The company has shown resilience in its financials, with projected revenues and net profits expected to grow in the coming years despite market fluctuations [4][22] - The company’s dividend payout ratio has increased, with a forecasted dividend yield of 4.8% based on recent share prices [4][26] Non-Coal Ventures - The company is pursuing non-coal mining opportunities, including a titanium project in Sierra Leone, which is expected to generate significant additional profits [3][54] - The project is structured in phases, with the first phase expected to contribute approximately 330 million yuan in gross profit [57] Diversification into Other Businesses - The company is diversifying into agriculture, real estate, and property management, with several projects underway that are expected to enhance overall revenue [59][61] - The real estate segment includes multiple high-quality projects across various cities, contributing to the company's revenue diversification strategy [59][61]

证券研究报告：电子 | 公司点评报告 发布时间：2026-02-09 股票投资评级 买入 |首次覆盖 个股表现 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（港币） | 103.70 | | --- | --- | | 总股本/流通股本（亿股） | 4.34 / 3.52 | | 总市值/流通市值（亿港币）449.58 / 365.49 | | | 52 周内最高/最低价 | 136.90 / 85.60 | | 资产负债率(%) | 9.85% | | 市盈率 | -18.1 | | 第一大股东 | 彭军 | 研究所 分析师:吴文吉 SAC 登记编号:S1340523050004 Email:wuwenji@cnpsec.com 小马智行(2026.HK) 智能驾驶龙头，Robotaxi 商业化初步落地 ⚫ 事件 2026 年 2 月 4 日，公司发布 2025 年业绩预告：2025 年度预期亏 损约 69.0 百万美元至 86.0 百万美元，较 2024 年度的 275.0 百万美 元大幅收窄约 68.7%至 74.9%；亏损收窄主因系报告期内对上市公司 的投资公允价值变动收益增长所致。 ...

证券研究报告：电子 | 公司点评报告 发布时间：2026-02-09 股票投资评级 买入 |首次覆盖 个股表现 资料来源：聚源，中邮证券研究所 公司基本情况 | 最新收盘价（港币） | 103.70 | | --- | --- | | 总股本/流通股本（亿股） | 4.34 / 3.52 | | 总市值/流通市值（亿港币）449.58 / 365.49 | | | 52 周内最高/最低价 | 136.90 / 85.60 | | 资产负债率(%) | 9.85% | | 市盈率 | -18.1 | | 第一大股东 | 彭军 | 研究所 智能驾驶龙头，Robotaxi 商业化初步落地 ⚫ 事件 2026 年 2 月 4 日，公司发布 2025 年业绩预告：2025 年度预期亏 损约 69.0 百万美元至 86.0 百万美元，较 2024 年度的 275.0 百万美 元大幅收窄约 68.7%至 74.9%；亏损收窄主因系报告期内对上市公司 的投资公允价值变动收益增长所致。 ⚫ 投资要点 广州 UE 模型率先转正，Robotaxi 商业化路径初步验证，2026 年 车队规模有望预计达 3000 台。截至 2025 ...

Investment Rating - The report assigns an "Accumulate" rating for the company, marking its first coverage [5]. Core Insights - The company, "Yujian Xiaomian," is the leading brand in the Sichuan-Chongqing flavor noodle restaurant sector in China, employing a dual model of direct operation and franchising. It was founded in 2014 and is projected to become the largest Sichuan-Chongqing flavor noodle restaurant by 2024, with plans for an IPO in 2025 [1][21]. - The company has experienced continuous revenue growth and has turned profitable through price reductions and effective raw material cost control, despite facing challenges such as high debt and rental pressures from store expansions [1][3]. - The Sichuan-Chongqing flavor noodle market is witnessing a resurgence in expansion following industry consolidation, with a notable increase in popularity and a clear trend towards chain operations, particularly in lower-tier markets [1][2]. Summary by Sections 1. Company Overview - Yujian Xiaomian is recognized as the top Sichuan-Chongqing flavor noodle restaurant in China, utilizing a combination of direct operation and franchising [1]. - The company has expanded its menu to include a variety of noodle dishes, rice, snacks, and beverages, catering to a wide demographic and operating in various locations [21]. 2. Market Dynamics - The Chinese noodle restaurant industry is steadily growing, with Sichuan-Chongqing flavors gaining popularity. The market is highly fragmented, with the top five companies holding only 2.9% market share [1][2]. - The company is positioned as the fourth largest in the Chinese noodle restaurant sector and the fastest-growing in the Sichuan-Chongqing category [1]. 3. Growth Strategy - The company is focusing on market penetration in lower-tier cities, with the number of stores in these areas increasing from 30 to 76 between 2022 and 2025 [3]. - The franchise model is being implemented with a strategy of "slow expansion, strong control," ensuring quality through a unified supply chain [3]. 4. Financial Projections - Revenue is expected to grow significantly, with forecasts of 1.15 billion CNY in 2024 and 1.66 billion CNY in 2025, reflecting growth rates of 44.2% and 43.8% respectively [4]. - The company anticipates net profits of 105 million CNY in 2025, with an EPS of 0.15 CNY, and a corresponding P/E ratio of 32X [4][13]. 5. Operational Efficiency - The company has implemented a digital system to enhance operational efficiency across all business segments, leveraging real-time data to improve performance [2]. - Despite rapid expansion, the company faces challenges in maintaining store efficiency, with average daily sales per store showing a declining trend [41]. 6. Competitive Advantages - Yujian Xiaomian's competitive edge lies in its diversified offerings, standardized management practices, and strong capital backing from notable investors [2][3]. - The company has successfully reduced raw material costs from 38.3% in 2022 to 31.4% in 2025, showcasing effective cost management strategies [49].

2026 年 02 月 09 日 王睿哲 C0062@capital.com.tw 目标价(港币) 98 公司基本资讯 | 产业别 | | 医药生物 | | --- | --- | --- | | H 股价(2026/02/06) | | 79.50 | | 恒生指数(2026/02/06) | | 26560.00 | | 股价 12 个月高/低 | | 107.00 / 33.05 | | 总发行股数(百万) | | 1735.19 | | H 股数(百万) | | 1735.19 | | H 市值(亿港币) | | 1379.47 | | 主要股东 | | 俞德超(5.36%) | | 每股净值(港币) | | 9.8324 | | 股价/帐面净值 | | 8.0855 | | | 一个月 三个月 | 一年 | | 股价涨跌(%) | -10.97 -6.69 139.82 | | 近期评等 | 出刊日期 | 前日收盘 | 评等 | | --- | --- | --- | | 2025/10/22 | 88.00 | 买进 | | 产品组合 | | | --- | --- | | 药品销售 | 87% ...

Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The company is expected to achieve a net profit of 2.15-2.25 billion yuan for FY26H1, representing a year-on-year increase of 216%-231%. After considering perpetual bonds, the attributable net profit is projected to be 1.95-2.05 billion yuan, reflecting a year-on-year growth of 315.2%-336.5%. This strong performance is primarily due to increased product sales volume, rising sales prices, and a decrease in raw material costs leading to a significant increase in gross profit [1] - The scale effect of pulp production is becoming evident, with the company's pulp production capacity in Guangxi coming online. This has resulted in a rapid reduction in pulping costs and an increase in the self-supply ratio of pulp, which are key factors driving the company's performance beyond expectations [2] - The pulp segment is contributing significantly to profits, while the waste paper segment is showing improvement in profitability. Despite cultural and white card paper prices being at historical lows, the company is still able to generate profit increments due to its self-produced pulp advantage. By FY25, the company’s production capacity for white card and cultural paper is expected to reach 1.8 million and 2.27 million tons, respectively, with further expansions planned for FY26H1 [3] - The company continues to expand its pulp production capacity, with total pulp capacity reaching 23.5 million tons by FY25. The focus remains on increasing the self-supply ratio of raw materials, with additional production capacity planned for FY26 and FY27. This ongoing expansion is expected to further enhance the company's profitability [4] Financial Summary - Revenue projections for FY26-FY28 are 72.67 billion, 73.99 billion, and 74.76 billion yuan, representing year-on-year growth of 15%, 2%, and 1%, respectively. The attributable net profit is forecasted to be 4.08 billion, 4.41 billion, and 5.04 billion yuan, with year-on-year increases of 131%, 8%, and 14%, respectively. The corresponding P/E ratios are 8.9, 8.3, and 7.2 times [4][9]